

Cahill Represents Lead Arrangers in Halozyme Therapeutics' \$750 Million Credit Facility

Date: 11/05/25

Cahill represented the lead arrangers in connection with an amendment to Halozyme Therapeutics, Inc.'s credit agreement to extend the maturity and increase the revolving credit facility by \$175 million to \$750 million.

Halozyme Therapeutics, Inc. is a biopharma technology platform company that provides innovative and disruptive solutions with the goal of improving patient experience and outcomes.

Attorneys

- Stuart Downing
- Alexa S. Kaminsky
- John Schekin
- Brendan Finnerty
- Gregory James

Practice

Banking & Finance